中山市医院肛肠专家(中山便便出鲜血) (今日更新中)

WASHINGTON, Aug. 24 (Xinhua) -- Online search engine Google Inc. has agreed to pay 500 million U.S. dollars to settle claims that it allowed online Canadian pharmacies to place advertisements targeting consumers in the United States, U.S. Justice Department announced Wednesday.The settlement, one of the largest ever in the United States, represents the gross revenue received by Google as a result of Canadian pharmacies advertising through Google's AdWords program, plus gross revenue made by Canadian pharmacies from their sales to U.S. consumers.The advertisements led to illegal imports of prescription drugs into the country, the Justice Department said.The shipment of prescription drugs from pharmacies outside the United States to customers in the United States typically violates the Federal Food, Drug and Cosmetic Act and in the case of controlled prescription drugs, the Controlled Substances Act.Google was aware as early as 2003, that generally, it was illegal for pharmacies to ship controlled and non-controlled prescription drugs into the United States from Canada."The Department of Justice will continue to hold accountable companies who in their bid for profits violate federal law and put at risk the health and safety of American consumers," Deputy Attorney General James Cole said in a statement."This settlement ensures that Google will reform its improper advertising practices with regard to these pharmacies while paying one of the largest financial forfeiture penalties in history," he said.Google had previously set aside that amount for a possible settlement over its advertising practices, according to a regulatory filing in May.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

THE HAGUE, June 24 (Xinhua) -- Bird flu was discovered at a poultry farm in the central Dutch province of Flevoland, the Ministry of Agriculture said Friday.It said the virus discovered was a mild variant. The farm's 47,000 chickens were slaughtered to prevent the virus turning into a contagious and deadly variant.It remains uncertain whether the chickens were infected with the high or low pathologene H7 variant. The low pathologene version can mutate into a high pathologen, which is extremely transmittable.Poultry from other farms in a zone of three kilometres of the contaminated farm will be tested. A prohibition of transport for poultry, eggs and poultry manure has been set.

BEIJING, Sept. 28 (Xinhuanet) -- The unmanned Shenzhou VIII, part of China's first spacecraft rendezvous and docking mission, will be launched in early November. Niu Hongguang, deputy commander-in-chief of the program, said on Tuesday the launch has not been affected by the postponed lift-off of the Tiangong-1 space module. Tiangong-1 was to enter a low orbit around Earth at the end of August before being met by Shenzhou VIII. However, the departure was pushed back after a satellite failure on Aug 18. Out of safety concerns, Niu said mission commanders ordered a halt to testing at Jiuquan Satellite Launch Center on Tiangong-1 and its carrier rocket, Long March II-F T1. China Aerospace Science and Technology Corp, which designed and made the rocket carrier that failed to launch, formed an expert panel to investigate and made modifications. A successful launch of a communication satellite on Sept 19 using the Long March II-C showed the measures worked, Niu said, adding: "We now have confidence in the launch of Tiangong-1." The module is a "simplified" space lab that will not only be a docking target, but will also work as a space experimental platform. It will be unmanned for most of its two years of use, although astronauts will spend time onboard for short periods. After Shenzhou VIII, the country will launch Shenzhou IX and Shenzhou X next year to rendezvous and dock with Tiangong-1. Niu confirmed Shenzhou X will be manned. Tiangong-1 can accommodate two to three astronauts. "Whether Shenzhou IX will be manned is up to the results of the first rendezvous and docking mission," he said. The rocket carrier with Tiangong-1 atop stands 52 meters tall, with a takeoff weight of 493 tons. Tiangong-1 was scheduled for launch in between Sept 27 and 30, but due to weather forecasts that predicted a cold air mass would move into the area of Jiuquan Satellite Launch Center, it is believed that conditions on Thursday and Friday will be suitable for takeoff.

PARIS, Aug. 19 (Xinhua) -- Marine scientists and representatives from the private sector and military establishments would meet at UNESCO at the end of this month to measure noise's impact on marine life, the Paris-based UN scientific branch UNESCO said Friday.The main agenda of the meeting, which is due from Aug. 30 to Sep. 1, was to discuss the program of the International Quiet Ocean Experiment (IQOE)."This decade-long project aims to fill the considerable knowledge gaps in this area, so that management of ocean noise can be more informed and effective," UNESCO said in a statement.The Quiet Ocean Experiments was initiated against the background that human activities on the high seas have increased significantly in recent decades, and resulted in impact upon many marine species relying mainly on sound to communicate.However, some sounds are suspected to alter the behavior of marine animals. For example, several whale species have raised the volume of the squeaks, clicks and moans by which they communicate with each other.The experiment is organized by the Scientific Committee on Oceanic Research (SCOR) and the Partnership for Observation of the Global Oceans (POGO), of which UNESCO's Intergovernmental Oceanographic Commission (IOC) is a member.

来源：资阳报